European drug discovery platform emerges in €196M effort

Europe's pharma community is revving up a drug discovery engine. A new effort involving 30 partners--including Bayer, Johnson & Johnson's ($JNJ) Janssen and 5 other large pharmas--has launched to spark discovery of new treatments, using a crowdsourcing and open-innovation approach. Don't expect them to pull off the effort without software support. One of the 30 project partners is ChemAxon, a Budapest, Hungary-based provider of chemical informatics and desktop software. Article

Suggested Articles

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.

TriNetX's platform uses EHR data to help drug developers with clinical trial protocol design and study site and participant identification.

The $58 million financing round represents biopharma industry's growing interest in genomics data.